17. Segment and Geographic Information (Details Narrative) (USD $)
|
12 Months Ended | |
---|---|---|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
Product licensing fees and royalties | $ 3,056,000us-gaap_LicensesRevenue | $ 5,513,000us-gaap_LicensesRevenue |
Exeltis | ||
Product licensing fees and royalties |
437,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_ExeltisMember |
807,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_ExeltisMember |
Onset | ||
Product licensing fees and royalties |
0us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_OnsetMember |
27,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_OnsetMember |
Innovacyn | ||
Product licensing fees and royalties |
1,120,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_InnovacynMember |
3,100,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_InnovacynMember |
Laboratorios Sanfer | ||
Product licensing fees and royalties |
1,499,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_LaboratoriosSanferMember |
1,501,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_LaboratoriosSanferMember |
China Distributor | ||
Product licensing fees and royalties |
$ 0us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_ChinaDistributorMember |
$ 78,000us-gaap_LicensesRevenue / us-gaap_StatementBusinessSegmentsAxis = ocls_ChinaDistributorMember |
X | ||||||||||
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|